Exclusive Cooperation between ARTES and the Ukrainian National Academy of Sciences

Langenfeld/Lviv, (PresseBox) - ARTES announced today that it has signed an exclusive Marketing Agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. Matter of the agreement is that the NAS technology based on the yeast organism Hansenula polymorpha is now exclusively marketed and licensed by ARTES Biotechnology worldwide except for Ukraine.

The technology licensed to ARTES covers new expression tools as well as production cell lines for various products, a.o. HepB antigen and Arginase. With this agreement ARTES expands its Hansenula technology platform and gains access to new processes and products.

"With the input from NAS", said Michael Piontek the managing director from ARTES, "we are now once again able to broaden up our expertise in the Hansenula research field. This newest collaboration enables us even more to expand our previous offer and especially with the view of East-European markets we had won an important academic research partner."

ARTES Biotechnology GmbH

ARTES is a Germany-based biotechnology company specialized in recombinant protein production from yeast expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha and Arxula adeninivorans. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld near Duesseldorf. The company is a strategic partner for the chemical and pharmaceutical industry, developing cost-efficient production processes for internationally marketed products on a contract R&D basis.

www.artes-biotechnology.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.